Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Tommaso Clemente

Ospedale San Raffaele

Italy

Research Interests

Explore related searches

Professors in Italy

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (10)

Giuseppe LAPADULA

Docenti di ruolo di IIa fascia

University of Milano-Bicocca

ITALY

View details

Silvia Nozza

Vita-Salute San Raffaele University

ITALY

View details

Federico D'AMICO

University of Milan

ITALY

View details

Antonio Di Biagio

University of Genoa

ITALY

View details

GIULIA CARLA MARCHETTI

University of Milan

ITALY

View details

Pierluigi Reali

Assistant Professor

Politecnico di Milano

ITALY

View details

Vincenzo Spagnuolo

Vita-Salute San Raffaele University

ITALY

View details

Antonio Cascio

University of Palermo

ITALY

View details

Alessandra Bandera

Associate Professor

University of Milan

ITALY

View details

Massimiliano Fabbiani

Docenti di ruolo di IIa fascia

University of Siena

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tommaso Clemente

Research Interests

Explore related searches

Articles (20)

Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort

Effectiveness of switching regimen in people living with HIV and persistent low‐level viraemia in the modern antiretroviral treatment era

Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

First virological control after >30 years of antiretroviral therapy in extensively drug-resistant HIV: potential role of lenacapavir plus ibalizumab

Hepatitis B Reactivation in People With HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen

Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV

Significant Impact of Previous Major Cardiovascular Events (MACEs) and Viremia on Risk of New MACEs in People Living with HIV on Antiretroviral Therapy

Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era

Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry

All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry

Anti-cluster A and anti-p24 antibodies in people with multidrug-resistant HIV: Preliminary observations from the PRESTIGIO registry

Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry

Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of Steatosis

Prevalence of Sexually Transmitted Infections Among Cisgender Women Coming to a Walk-In Center

Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry

Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting

Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry

Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry

One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study

Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry

Collaborators (10)

Giuseppe LAPADULA

Silvia Nozza

Federico D'AMICO

Antonio Di Biagio

GIULIA CARLA MARCHETTI

Pierluigi Reali

Vincenzo Spagnuolo

Antonio Cascio

Alessandra Bandera

Massimiliano Fabbiani

Make your next move.

Tommaso Clemente

Research Interests

Explore related searches

Articles (20)

Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort

Effectiveness of switching regimen in people living with HIV and persistent low‐level viraemia in the modern antiretroviral treatment era

Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

First virological control after &gt;30 years of antiretroviral therapy in extensively drug-resistant HIV: potential role of lenacapavir plus ibalizumab

Hepatitis B Reactivation in People With HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen

Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV

Significant Impact of Previous Major Cardiovascular Events (MACEs) and Viremia on Risk of New MACEs in People Living with HIV on Antiretroviral Therapy

Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era

Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry

All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry

Anti-cluster A and anti-p24 antibodies in people with multidrug-resistant HIV: Preliminary observations from the PRESTIGIO registry

Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry

Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of Steatosis

Prevalence of Sexually Transmitted Infections Among Cisgender Women Coming to a Walk-In Center

Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry

Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting

Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry

Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry

One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study

Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry

Collaborators (10)

Giuseppe LAPADULA

Silvia Nozza

Federico D'AMICO

Antonio Di Biagio

GIULIA CARLA MARCHETTI

Pierluigi Reali

Vincenzo Spagnuolo

Antonio Cascio

Alessandra Bandera

Massimiliano Fabbiani

Make your next move.

First virological control after >30 years of antiretroviral therapy in extensively drug-resistant HIV: potential role of lenacapavir plus ibalizumab